"Tumor Rejection by Vaccination with Engineered Antigen Presenting Cells and Melanoma Acid Extracts."

According to an abstract submitted by the authors to the International Symposium on Clinical Immunology, held July 20-23, 1995, in San Francisco, California, "A cytotoxic T lymphocyte (CTL) response can be generated in vivo by immunization with RMA-S cells loaded with total acid peptide fraction (TAPF, Mr<5000) of tumor cells. We recently demonstrated that RMA-S cells stably transfected with cDNA encoding for the human B7.1 costimulatory molecule (RMA-S/B7) acquire a high and sometimes unique efficiency for in vitro primary CTL induction. Most importantly, RMA-S/B7 cells, loaded with TAPF from the poorly immunogenic B16 melanoma cells (TAPF-B16) were able to prime CD8⁺...

Want to see the full article?

• Purchase this article for only $3.00